Stockscreener 앱 받기
3.65
5.49%
0.19
시간 외 거래:
3.60
-0.05
-1.37%
전일 마감가:
$3.46
열려 있는:
$3.62
하루 거래량:
15,181
Relative Volume:
0.11
시가총액:
$4.62M
수익:
$204.80K
순이익/손실:
$-8.27M
주가수익비율:
-0.4012
EPS:
-9.097
순현금흐름:
$-2.63M
1주 성능:
+7.35%
1개월 성능:
-6.41%
6개월 성능:
-43.89%
1년 성능:
-59.60%
1일 변동 폭
$3.52
$3.80
1주일 범위
$3.23
$3.80
52주 변동 폭
$3.10
$11.97
Addex Therapeutics Ltd Adr Stock (ADXN) Company Profile
Compare ADXN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADXN
Addex Therapeutics Ltd Adr
|
3.65 | 4.62M | 204.80K | -8.27M | -2.63M | -9.097 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Addex Therapeutics Ltd Adr Stock (ADXN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
Addex Therapeutics Ltd Adr 주식(ADXN)의 최신 뉴스
Teyssedou Lenaic Nathanael Reports 502,423 Derivative Securities After Recent Disposals at Addex Therapeutics - kalkinemedia.com
Kalinichev Mikhail Receives 306,765 Shares and 200,000 Derivative Securities from Addex Therapeutics - kalkinemedia.com
Hill Raymond George Discloses Award and Disposal of 1.37M Addex Therapeutics Shares and Derivative Securities - Kalkine Media
Hill Raymond George Announces Award and Disposal of 1.37M Addex Therapeutics Shares and Derivative Securities - kalkinemedia.com
Manke Isaac Adjusts Holdings in Addex Therapeutics with 219,561 Shares and 50,000 Derivatives on September 2, 2026 - kalkinemedia.com
Addex Therapeutics LtdADR Peer Comparison – Compare with Others - Value Research
Timothy Mark Dyer Discloses 8.98% Stake in Addex Therapeutics (NASDAQ: ADXN) - kalkinemedia.com
Addex Therapeutics Ltd Sponsored ADR Revenue Breakdown – MUN:APE1 - TradingView
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness - Barchart.com
Addex Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ADXN) - TradingView
Enterprise value to revenue forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Price to earnings forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Price to sales forward of Addex Therapeutics Ltd Sponsored ADR – LSX:A3EXC6 - TradingView
Earnings call transcript: Addex Therapeutics trims loss in Q1 2026 as cash burn stays low - Investing.com India
Addex Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 - Barchart.com
Addex Convenes Annual General Meeting 2026 - Barchart.com
ADXN - Finviz
Addex Therapeutics (NASDAQ: ADXN) flags tight cash runway and heavy partner reliance - Stock Titan
Addex Therapeutics H2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Addex Therapeutics H2 2026 reveals strategic shifts By Investing.com - Investing.com India
Earnings call transcript: Addex Therapeutics H2 2026 reveals strategic shifts - Investing.com
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update - Barchart.com
Addex Therapeutics announces GABAB PAM candidate data - TipRanks
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model - Barchart.com
Unusual VolumeStock ScreenerNews - Finviz
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2 - TipRanks
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model - Barchart.com
Addex Therapeutics Short Interest Drops in March - National Today
New HighStock ScreenerSnapshot - Finviz
Top GainersStock ScreenerSnapshot - Finviz
JX Luxventure Group Inc (NASDAQ:JXG) Short Interest Up 140.3% in February - Defense World
Addex Therapeutics (ADXN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Charcot Marie Tooth Disease Market on Track for Major Expansion by 2034, According to DelveInsight | DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharma - Barchart.com
ADXN SEC FilingsAddex Therapeutics Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
Addex Therapeutics (ADXN) Trading Halted Due to Volatility | ADX - GuruFocus
Addex Therapeutics Ltd_December 31, 2024 - SEC.gov
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Addex Therapeutics Ltd (ADR) (ADXN) Live Share Price, Invest From India - INDmoney
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Get insights into the top gainers and losers of Monday's pre-market session. - ChartMill
Which stocks are moving after the closing bell on Tuesday? - ChartMill
Addex Therapeutics (ADXN) Stock Forecast and Price Target 2026 - MarketBeat
Barinthus Biotherapeutics plc (BRNS) stock price, news, quote and history - Yahoo Finance UK
Barinthus Biotherapeutics plc (BRNS) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
Psyence Biomedical (PBM) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Thursday's pre-market session: top gainers and losers - ChartMill
Addex Therapeutics Ltd Adr (ADXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):